Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 4Observational 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Renal Insufficiency 1Osteosarcoma 1Neoplasms 1Lymphoma 1Leukemia 1

Interventions

tazemetostat 2regorafenib 2nirogacestat 2avapritinib 2Trabectedin 2selinexor 1ripretinib 1omburtamab I-131 1olaratumab 1mifamurtide 1glucarpidase 1ganitumab 1fludarabine phosphate 1balstilimab 1anlotinib 1Whole-Body Irradiation 1Tacrolimus 1TH 302 1Sunitinib 1Proton Pump Inhibitors 1Mycophenolic Acid 1Imatinib Mesylate 1Hydrocortisone 1FANG vaccine 1Everolimus 1DOXO-EMCH 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Carboxypeptidases 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × glucarpidase × Sarcoma × Clear all
NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡